Pharmaceutical Ingredient Ranitidine Hydrochloride CAS 66357-35-5

• Customization: Available
• Powder: Yes
• Customized: Non-Customized
• Model NO.: Pharmaceutical Grade
• Certification: GMP, HSE, ISO 9001, USP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >99%
• Ranitidine HCl: Light Yellow
• Transport Package: Drum
• Specification: 25kg
• Trademark: flying deer
• Origin: China
• Production Capacity: 260 Tons Yearly

Product Description

Pharmaceutical Ingredient Ranitidine Hydrochloride  CAS  66357-35-5
 

Product Name	Ranitidine Hcl
Package	25KG Drum
Description	White to pale yellow, crystalline practically odorless powder
Identification	A.The IR absorption spectrum of the test specimen comply with that of the corresponding USP Reference Standard B.Absorptivities at 229nm and 315nm ,do not differ by more than 3.0% C. A solution of it meets the requirements of Chloride.
pH	Should be 4.5~6.0
Loss on drying	≤0.75%
Residue on ignition	≤0.1%
Chromatographic purity	Ranitidine related Compound B: ≤0.5% Any other impurity:  ≤0.3% The sum of all impurities: ≤1.0%
Organic volatile impurities	Meet the requirements
Residual solvents	Alcohol: ≤0.5%
Assay	Assay (Dried basis C13H22N4O3S·HCl 97.5%~102%)

Ranitidine, N-[2-[[[5-(dimethylamino)methyl]-2-furanyl]methyl]thiol] ethyl]-N'-methyl-2-nitro-l,1-ethenediamine (Zantac), is a white solid, which inits hydrochloride salt form is highly soluble in water. It is anaminoalkyl derivative with pKa values of 2.7 (sidechain) and 8.2 (dimethylamino). Ranitidine is more potentthan cimetidine, but less potent than famotidine. Likeother H2-antagonists, it does not appear to bind to otherreceptors.
Bioavailability of an oral dose of ranitidine is about 50%and is not significantly affected by the presence of food.Some antacids may reduce ranitidine absorption and shouldnot be taken within 1 hour of administration of this drug. Theplasma half-life of the drug is 2 to 3 hours, and it is excretedalong with its metabolites in the urine. Three metabolites, ranitidineN-oxide, ranitidine S-oxide, and desmethyl ranitidine,have been identified. Ranitidine is only a weak inhibitor ofthe hepatic cytochrome isozymes, and recommended doses ofthe drug do not appear to inhibit the metabolism of otherdrugs. However, there have been isolated reports of drug interactions(warfarin, triazolam) that suggest that ranitidinemay affect the bioavailability of certain drugs by someunidentified mechanism, perhaps by pH-dependent effect onabsorption or a change in volume of distribution.
In addition to being available in various dosage forms asthe hydrochloride salt, ranitidine is also available as a bismuthcitrate salt for use with the macrolide antibiotic clarithromycinin treating patients with an active duodenalulcer associated with H. pylori infection. Eradication of H.pylori reduces the risk of duodenal ulcer recurrence.